CORE LABS INC (CLB)
(Delayed Data from NYSE)
$19.31 USD
+0.41 (2.17%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $19.34 +0.03 (0.16%) 5:00 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.31 USD
+0.41 (2.17%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $19.34 +0.03 (0.16%) 5:00 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Zacks News
SLB vs. CLB: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SLB vs. CLB: Which Stock Is the Better Value Option?
SLB or CLB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SLB vs. CLB: Which Stock Is the Better Value Option?
Core Labs (CLB) Q2 Earnings Meet Estimates, Sales Narrowly Beat
by Zacks Equity Research
Core Laboratories' (CLB) second-quarter earnings meet the consensus mark, while revenues marginally outperform the same.
Core Laboratories (CLB) Q2 Earnings Match Estimates
by Zacks Equity Research
Core Laboratories (CLB) delivered earnings and revenue surprises of 0% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Core Laboratories (CLB) Q2 Earnings Expected to Decline
by Zacks Equity Research
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Core Laboratories (CLB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Core Laboratories (CLB) stock based on the movements in the options market lately.
Core Laboratories (CLB) Up 2.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Core Labs (CLB) Stock Down 3% Since Q1 Earnings & Sales Beat
by Zacks Equity Research
Core Laboratories' (CLB) stock down 3% since the company's first-quarter earnings and revenues beat estimates.
Core Laboratories (CLB) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Core Laboratories (CLB) delivered earnings and revenue surprises of 33.33% and 3.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Core Laboratories (CLB) This Earnings Season?
by Zacks Equity Research
Core Laboratories (CLB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline
by Zacks Equity Research
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oil & Gas Stock Roundup: Oilfield Service Giants Decide to Move From Russia
by Nilanjan Choudhury
Apart from Russia-related updates from Halliburton (HAL), Schlumberger (SLB) and Core Laboratories (CLB), there was news regarding The Williams Companies (WMB) and Eni (E) during the week.
Core Labs (CLB) Hit by Russia Conflict, Pegs Down Q1 View
by Zacks Equity Research
In addition to the geopolitical risks, Core Laboratories (CLB) suffered operational hiccups after a much larger-than-usual number of its employees tested positive for COVID during the first quarter.
Core Laboratories (CLB) Moves 14.2% Higher: Will This Strength Last?
by Zacks Equity Research
Core Laboratories (CLB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Core Laboratories (CLB) Up 7.1% Since Last Earnings Report?
by Zacks Equity Research
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Core Labs (CLB) Q4 Earnings Meet Estimates, Revenues Surpass
by Zacks Equity Research
Core Laboratories' (CLB) fourth-quarter earnings are on par with the consensus mark, while revenues beat estimates as a result of a strong performance in the Production Enhancement segment.
Core Laboratories (CLB) Meets Q4 Earnings Estimates
by Zacks Equity Research
Core Laboratories (CLB) delivered earnings and revenue surprises of 0% and 1.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Core Laboratories (CLB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schlumberger (SLB) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Schlumberger (SLB) delivered earnings and revenue surprises of 5.13% and 2.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ExxonMobil (XOM) to Divest Iraq Assets After Receiving Approval
by Zacks Equity Research
ExxonMobil's (XOM) divestment of its West Qurna 1 stake would follow its 32% interest sale last year in a key exploration block in Iraq's Kurdistan region.
Core Labs' (CLB) Stock Up 9.4% Despite Missing on Q3 Earnings
by Zacks Equity Research
In the September quarter, Core Labs (CLB) generates $11.9 million as operating cash and its capex totals $3.1 million, leading to an $8.8-million free cash flow (FCF) recognition.
Core Laboratories (CLB) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Core Laboratories (CLB) delivered earnings and revenue surprises of -5.26% and -4.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Core Laboratories (CLB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Core Laboratories (CLB) Down 19.4% Since Last Earnings Report?
by Zacks Equity Research
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Core Labs' (CLB) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
In the June quarter, Core Labs (CLB) generates $9.5 million in operating cash and its capital expenditure totals $2.9 million, leading to a $6.6-million free cash flow (FCF) recognition.